Advanced search
Publication Cover
Future Oncology Volume 14, 2018 - Issue 21
Submit an article Journal homepage
200
Views
4
CrossRef citations to date
0
Altmetric
Research Article

Optimizing Intrapleural Bevacizumab Dosing in Non-Small-Cell Lung Cancer-Mediated Malignant Pleural Effusion: Less is More

Dawei Chen1 Department of Radiotherapy, Shandong Cancer Hospital Affiliated to Shandong University, Jinan250117, Shandong, PR ChinaView further author information
,
Xinyu Song2 School of Medicine & Life Sciences, University of Jinan-Shandong Academy of Medical Sciences, Jinan250000, Shandong, PR China;3 Department of Internal Medicine-Oncology, Shandong Cancer Hospital & Institute, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Sciences, Jinan250117, Shandong, PR ChinaView further author information
,
Yan Zhang1 Department of Radiotherapy, Shandong Cancer Hospital Affiliated to Shandong University, Jinan250117, Shandong, PR ChinaView further author information
,
Li Kong1 Department of Radiotherapy, Shandong Cancer Hospital Affiliated to Shandong University, Jinan250117, Shandong, PR ChinaView further author information
,
Haiyong Wang3 Department of Internal Medicine-Oncology, Shandong Cancer Hospital & Institute, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Sciences, Jinan250117, Shandong, PR ChinaCorrespondence[email protected]
View further author information
&
Jinming Yu1 Department of Radiotherapy, Shandong Cancer Hospital Affiliated to Shandong University, Jinan250117, Shandong, PR China;2 School of Medicine & Life Sciences, University of Jinan-Shandong Academy of Medical Sciences, Jinan250000, Shandong, PR ChinaCorrespondence[email protected]
View further author information
Pages 2131-2138 | Received 30 Jan 2018, Accepted 28 Feb 2018, Published online: 16 Mar 2018

References

  • Martínez-Moragón E , AparicioJ, SanchisJ, MenéndezR, CruzRogado M, SanchisF. Malignant pleural effusion: prognostic factors for survival and response to chemical pleurodesis in a series of 120 cases. Respiration65(2), 108–113 (1998).
  • Antony VB , LoddenkemperR, AstoulPet al. Management of malignant pleural effusions. Eur. Respir. J.18(2), 402–419 (2001).
  • Tao H , MengQ, LiM, ShiL, TangJ, LiuZ. Outcomes of bevacizumab combined with chemotherapy in lung adenocarcinoma-induced malignant pleural effusion. Thorac. Cancer9(2), 298–304 (2018).
  • Hou W , SanyalAJ. Ascites: diagnosis and management. Med. Clin. North Am.93, 801–817 (2009).
  • Becker G , GalandiD, BlumHE. Malignant ascites: systematic review and guideline for treatment. Eur. J. Cancer42, 589–597 (2006).
  • Kobold S , Hegewisch-BeckerS, OechsleK, JordanK, BokemeyerC, AtanackovicD. Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites?Oncologist14, 1242–1251 (2009).
  • El-Shami K , ElsaidA, El-KermY. Open-label safety and efficacy pilot trial of intraperitoneal bevacizumab as palliative treatment in refractory malignant ascites. J. Clin. Oncol.25(18S), 9043–9043 (2007).
  • Jordan K , LuetkensT, GogCet al. Intraperitoneal bevacizumab for control of malignant ascites due to advanced-stage gastrointestinal cancers: a multicentre double-blind, placebo-controlled Phase II study – AIO SUP-0108. Eur. J. Cancer63, 127–134 (2016).
  • Jiang L , LiP, GongZet al. Effective treatment for malignant pleural effusion and ascites with combined therapy of bevacizumab and cisplatin. Anticancer Res.36(3), 1313–1318 (2016).
  • Zhao H , LiX, ChenDet al. Intraperitoneal administration of cisplatin plus bevacizumab for the management of malignant ascites in ovarian epithelial cancer: results of a Phase III clinical trial. Med. Oncol.32(2), 292 (2015).
  • Du N , LiX, LiFet al. Intrapleural combination therapy with bevacizumab and cisplatin for non-small-cell lung cancer-mediated malignant pleural effusion. Oncol. Rep.29(6), 2332–2340 (2013).
  • Bellati F1 , NapoletanoC, RuscitoIet al. Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review. Invest. New Drugs28(6), 887–894 (2009).
  • Hamilton CA1 , MaxwellGL, ChernofskyMR, BernsteinSA, FarleyJH, RoseGS. Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer. Gynecol. Oncol.111(3), 530–532 (2008).
  • Chen D , ZhangY, ShiFet al. Intrapericardial bevacizumab safely and effectively treats malignant pericardial effusion in advanced cancer patients. Oncotarget7(32), 52436–52441 (2016).
  • Dowlati A , RobertsonK, RadivoyevitchTet al. Novel Phase I dose de-escalation design trial to determine the biological modulatory dose of the antiangiogenic agent SU5416. Clin. Cancer Res.11(21), 7938–7944 (2005).
  • Sleijfer S , WiemerE. Dose selection in Phase I studies: why we should always go for the top. J. Clin. Oncol.26(10), 1576–1578 (2007).
  • von Manstein V , YangCM, RichterD, DelisN, VafaizadehV, GronerB. Resistance of cancer cells to targeted therapies through the activation of compensating signaling loops. Curr. Signal. Transduct. Ther.8(3), 193–202 (2013).
  • Sack U , Homann M, ZhaoXJet al. Vascular endothelial growth factor in pleural effusions of different origin. Eur. Respir. J.25, 600–604 (2005).
  • Ribeiro SC , VargasFS, AntonangeloLet al. Monoclonal anti-vascular endothelial growth factor antibody reduces fluid volume in an experimental model of inflammatory pleural effusion. Respirology14(8), 1188–1193 (2009).
  • Luo JC , YamaguchiS, ShinkaiA, ShitaraK, ShibuyaM. Significant expression of vascular endothelial growth factor/vascular permeability factor in mouse ascites tumors. Cancer Res.58(12), 2652–2660 (1998).
  • Keunen O , JohanssonM, OudinAet al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc. Natl Acad. Sci. USA108(9), 3749–3754 (2011).
  • Zhou WB , BaiM, JinY. Diagnostic value of vascular endothelial growth factor and endostatin in malignant pleural effusions. Int. J. Tuberc. Lung Dis.13(3), 381–386 (2009).
  • Licht T , GoshenI, AvitalAet al. Reversible modulations of neuronal plasticity by VEGF. Proc. Natl Acad. Sci. USA108(12), 5081–5086 (2011).
  • Bag AK , KimH, GaoYet al. Prolonged treatment with bevacizumab is associated with brain atrophy: a pilot study in patients with high-grade gliomas. J. Neurooncol.122(3), 585–593 (2015).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.